Telum Therapeutics Names Dr. Subhendu Basu As CEO To Spearhead Next Development Phase

Telum Therapeutics, a biotechnology firm at the forefront of developing novel antibacterial agents to tackle multidrug-resistant infections, has announced the appointment of Dr. Subhendu Basu as its new Chief Executive Officer. With a career spanning over 20 years in academia and the biotech industry, Dr. Basu brings a wealth of experience in bio pharma leadership, particularly in immunology and infectious diseases. His appointment marks a significant milestone for Telum as it embarks on its next development phase, focusing on strategy refinement, pipeline expansion, and corporate development.

Dr. Basu's previous role as President and Chief Operating Officer at Adaptive Phage Therapeutics showcased his ability to lead a company through expansion and innovation. His efforts were instrumental in the company's merger with BiomX, highlighting his expertise in raising capital and driving product development milestones. Prior to this, Dr. Basu played a key role in enriching a NYSE-listed company's portfolio through technical assessments for mergers and acquisitions, contributing to the addition of 10 marketed products and numerous pipeline assets.

"I am truly inspired by Telum's dynamic pipeline and the team's accomplishments thus far," said Dr. Basu. "As CEO, I am eager to collaborate with the Telum scientific team and our dedicated investors to spur growth and advance Telum's investigational products into clinical trials for patient benefit."

With Dr. Basu's joining, Roberto Díez-Martínez, PhD, the founding CEO of Telum Therapeutics, transitions to Chief Operating Officer. Under his leadership, Telum developed its proprietary APEX platform, which has yielded new antimicrobial agents derived from endolysins with broad-spectrum antibacterial efficacy. Dr. Díez-Martínez has also played a crucial role in strengthening the company's scientific leadership and establishing a premier Scientific Advisory Board.

"After years of progress at Telum, I warmly welcome Dr. Basu as the new CEO," remarked Dr. Díez-Martínez. "I am confident that his leadership will drive significant advancements in infectious disease treatment through innovative technology like endolysin-based phage lysin enzyme platforms (EPLEs)."

Dr. Basu's vision for Telum Therapeutics involves advancing candidates to the clinic, expanding the portfolio of novel engineered lysins, and establishing strategic partnerships to fully exploit the APEX platform's potential.

About Telum Therapeutics: Founded in Navarra in 2019 by Roberto Díez and Rubén Díez, Telum Therapeutics is a global drug discovery biotechnology company dedicated to developing new treatments for infectious diseases using lytic enzymes from bacteriophages, known as enzybiotics. In 2020, the company successfully raised its first round of financing from Invivo Ventures, with co-investment from Clave Capital and CDTI-Innvierte.

For enquiries contact: [email protected]